Novartis wins European recs for a pair of new Cosentyx uses

With a raft of next-gen psoriasis competitors coming up Big Pharma's pipelines, Novartis ($NVS) is looking to distinguish Cosentyx by adding a pair of new uses. And it got one step closer on Friday, winning approval recommendations from European regulators for use of the med in both psoriatic arthritis and ankylosing spondylitis. Release

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.